Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences Inc (NQ: RXDX )

111.89 +2.20 (+2.01%)
Streaming Delayed Price Updated: 12:16 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prometheus Biosciences Inc

< Previous 1 2 3 Next >
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Prometheus Biosciences
Via Globe NewsWire
Analyst Expectations for Prometheus Biosciences's Future
 
Via Benzinga
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via Globe NewsWire
Analyst Expectations for Prometheus Biosciences's Future
 
Via Benzinga
Looking Into Prometheus Biosciences's Return On Capital Employed
 
Via Benzinga
Where Prometheus Biosciences Stands With Analysts
 
Via Benzinga
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
From Prometheus Biosciences
Via Globe NewsWire
How Is The Market Feeling About Prometheus Biosciences?
Prometheus Biosciences's (NASDAQ:RXDX) short percent of float has fallen 35.76% since its last report. The company recently reported that it has 3.43 million shares sold short, which is 8.3% of all... 
Via Benzinga
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Prometheus Biosciences
Via Globe NewsWire
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Prometheus Biosciences Stock Is Falling
Prometheus Biosciences Inc (NASDAQ: RXDX) shares are trading lower by 6.01% to $110.16 going into the close of Friday's session after the company priced a public upsized $500 million offering. 
Via Benzinga
Is Prometheus Biosciences a Good Stock to Buy Right Now?
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead. 
Via The Motley Fool
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
From Prometheus Biosciences
Via Globe NewsWire
Why Prometheus Biosciences Stock Is Rocketing Higher Today
Prometheus Biosciences Inc (NASDAQ: RXDX) shares are trading higher Thursday after multiple analyst firms raised price targets on the stock following positive results from the company's PRA023 in both 
Via Benzinga
Analyzing Prometheus Biosciences's Short Interest
Prometheus Biosciences's (NASDAQ:RXDX) short percent of float has risen 5.39% since its last report. The company recently reported that it has 4.89 million shares sold short, which is 13.3% of all... 
Via Benzinga
Why Shares of Prometheus Biosciences Are Soaring This Week
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy. 
Via The Motley Fool
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
 
Via Benzinga
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds. 
Via Benzinga
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
From Prometheus Biosciences
Via Globe NewsWire
Dow Edges Higher; Prometheus Biosciences Shares Jump
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
Prometheus Biosciences (NASDAQ: RXDX) Reports PRA023 Candidate Achieved Positive Results in Both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Clinical Trials
Prometheus Biosciences, Inc. (NASDAQ: RXDX) is engaged as a clinical-stage biotechnology company, which is focused on the research, development and 
Via Spotlight Growth
Nasdaq Drops 75 Points; Crude Oil Down 2%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping 75 points on Wednesday. 
Via Benzinga
Dow Bounces Back From Morning Selloff
The Dow Jones Industrial Average is trying to claw back from the market's multi-day selloff. Meanwhile, the S&P 500 Index and Nasdaq Composite Index continue to flag near breakeven. 
Via Talk Markets
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.